Daniel Passeri - Jul 21, 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Jul 21, 2023
Transactions value $
$0
Form type
4
Date filed
7/25/2023, 12:28 PM
Previous filing
Feb 21, 2023
Next filing
Aug 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +450K $0.00 450K Jul 21, 2023 Common Stock 450K $4.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023.